Hematological malignancies are known to have a multitude of aberrations across the genome, including fusion genes, somatic mutations such as single nucleotide variants (SNVs) and insertions/deletions (indels), and copy number variations (CNVs) such as duplications, deletions, loss of heterozygosity (LOH), copy neutral LOH (cnLOH), ploidy, and more. Yet no one technology can efficiently assess all of these aberration types, making the profiling of hematological malignancy samples time and labor intensive.
Streamline your comprehensive hematological cancer sample profiling. Our proven next-generation sequencing (NGS) (Oncomine Myeloid Research Assay) and microarray (CytoScan HD Suite) technologies, together with combined reporting through Oncomine Reporter, offer:
Go from sample to answer in under three days using CytoScan HD Suite and Oncomine Myeloid Research Assay in parallel. When used together, these proven technologies enable comprehensive, cost-effective analysis for hematological malignancy samples, with results in a single report.
While the detection of global CNVs or the screening of somatic mutations and fusion genes using a single panel are game changers for comprehensive, accurate profiling of hematological malignancy samples, some labs may not have the necessary equipment or expertise to perform such assays or may require result confirmation by an orthogonal technique. We also offer established technologies such as real-time PCR, Sanger sequencing, and fragment analysis for the detection of low-level fusion genes, somatic mutations, and CNVs in hematological cancer samples.